Income investors entering July 2026 are getting a friendlier setup than they had six months ago. The 10-year Treasury yield sits at 4%, down from its May 19 peak of 5%, and the Fed Funds upper bound has held at 4% for six months after two cuts in late 2025. Falling rates lower refinancing pressure on REITs and tighten the spread between bond coupons and equity dividend yields, which is exactly the macro backdrop where REIT cash distributions look most attractive.
Three names stand out for July: a blue-chip net-lease bellwether, an industrial warehouse compounder transitioning its payout cadence, and a healthcare landlord that just unlocked value through an IPO. All three trade on US exchanges, and two still cut monthly checks.
Here is the thesis on each.
Realty Income (O)
Realty Income (NYSE:O | O Price Prediction) remains the default holding for monthly passive income. The stock closed at $62.68 on June 29 with a market cap near $58.9 billion and a dividend yield around 5%. The latest monthly payout was raised to 27 cents per share in June 2026, payable July 15, extending an already exceptional streak: 132 increases since the 1994 IPO and 670 consecutive monthly dividends declared.
The bull case is the operating engine underneath the payout. Q1 2026 AFFO came in at $1.13 per share, up 7% year over year, on $1.55 billion of revenue, with portfolio occupancy at 99% and a rent recapture rate of 103%. Management raised 2026 AFFO guidance to $4.41 to $4.44 and lifted full-year investment volume guidance to $9.5 billion from $8.0 billion, helped by a $1.0 billion strategic partnership with Apollo. CEO Sumit Roy pointed to the “strength and resiliency of our global investment and operating platforms”.
Risk: valuation is full. Shares are up 14% year to date and trade at a trailing P/E near 52, leaving little room for error if rates reverse higher or if the $129.3 million in Q1 impairment provisions signal stress in underlying tenants.
STAG Industrial (STAG)
STAG Industrial (NYSE:STAG) is the most important caveat in this basket. STAG moved from monthly to quarterly payments in January 2026, so the popular “monthly dividend industrial REIT” label no longer applies. The current quarterly distribution is 38 cents per share, with the next payment scheduled for July 15. At a recent price of $38.99, the yield works out near 4%.
The bull case is operational momentum in single-tenant warehouses. Q4 2025 produced EPS of $0.44 vs. $0.22 expected, revenue of $220.9 million (up 11% YoY), and Core FFO of $0.66 per diluted share, up 8%. Operating portfolio occupancy was 97%, Q4 cash rent change came in at 16%, and full-year cash rent change hit 24%. Management has already addressed 69% of 2026 expected leasing at a 20% cash rent change, with an acquisition pipeline of $3.6 billion across 169 buildings. CEO Bill Crooker highlighted “financial and operational discipline”.
Risk: refinancing math. Term loan G stepped up from 2% to 4% in February 2026, and additional debt rolls will keep interest expense climbing even as the Fed holds steady. Investors who specifically wanted monthly checks should know the cadence has changed.
Healthpeak Properties (DOC)
Healthpeak Properties (NYSE:DOC) is the most contrarian pick of the three. The healthcare REIT switched to a monthly payout, currently 10 cents per share, putting the yield near 6% at the recent price of $21.62. Shares are up nearly 35% year to date and more than 12% in the past month alone.
The catalyst was the Janus Living IPO, which closed at the high end of its valuation range and delivered ~$880 million in net proceeds, with Healthpeak retaining an 82% stake in an entity now carrying a $6.9 billion market cap. Q1 2026 GAAP EPS of $0.28 crushed the $0.05 consensus, revenue of $752.95 million beat by 9%, and senior housing same-store cash NOI grew 14%. Management raised 2026 EPS guidance to $0.46 to $0.50 and FFO as Adjusted to $1.71 to $1.75. Capital return is also active: 5.9 million shares repurchased at an average $16.81 in April, with ~$306 million remaining on the authorization.
Risk: the lab segment. Lab same-store NOI fell 7% in Q1, and recovery depends on biopharma demand returning through year-end. Interest expense also rose to $87.3 million from $72.7 million.
What to Watch in July
If the 10-year keeps drifting lower toward the year’s February low of 4%, all three names get a relative-yield tailwind. The variable to track is lab leasing for Healthpeak, refinancing spreads for STAG, and AFFO conversion on the Apollo partnership for Realty Income. Income that arrives every month (or every quarter, in STAG’s case) is still the simplest reason to own this sector.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks